Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the open label extension for the patients who participated in this phase II study. We also started the development of the phase III clinical trial with this antiamyloid monoclonal antibody of EISAI / Biogen.
